loratadine / Generic mfg. - LARVOL DELTA

Motixafortide + G-CSF hematopoietic stem cell mobilization in patients with multiple myeloma following quadruplet induction therapy (ASH 2025) - P1, P3 | "All patients received"enhanced" premeds with: loratadine (10 mg, PO), famotidine (20 mg, PO) and montelukast (10 mg, PO)daily on Day 1-5; plus acetaminophen (975mg, PO), hydrocortisone (200 mg, IV), diphenhydramine (25mg, IV) and famotidine (20 mg, IV) on Day 4 (30-45 mins pre-M). Meanwhile,enhanced premeds were associated with a low rate of AEs relative to standard premeds. Ongoingextended immunophenotyping may shed insight into the mechanism of impaired HSC mobilization post-quad induction, possibly via targeted depletion of a large population of CD38+ HSCs within the CD34+graft."

Clinical • Dermatology • Hematological Malignancies • Multiple Myeloma • Pruritus • CD34

Efficacy of a Combination Therapy of Montelukast and Antihistamines in Allergic Rhinitis: A Systematic Review and Network Meta-Analysis. (PubMed, Allergy Asthma Immunol Res) - "The treatment strategies included montelukast alone, antihistamine monotherapies (loratadine, desloratadine, levocetirizine, and fexofenadine), their respective combinations with montelukast, including bilastine. Although some comparisons require cautious interpretation, montelukast-based combination therapy demonstrated greater efficacy than monotherapy for multiple AR symptoms. These results highlight the importance of selecting therapeutic strategies based on the predominant symptom profile of individual patients."

Journal • Retrospective data • Review • Allergic Rhinitis • Conjunctivitis • Immunology • Inflammation • Ocular Infections • Ocular Inflammation • Ophthalmology

Evaluating Premedication Regimens (Methylprednisolone vs Dexamethasone-based) for the Prevention of Systemic and Injection Site Reactions to Motixafortide in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization, PARADE Trial (clinicaltrials.gov) - P4 | N=94 | Recruiting | Sponsor: Emory University | Not yet recruiting ➔ Recruiting

Enrollment open • Allergy • Hematological Malignancies • Multiple Myeloma • Oncology

The use of antihistamine and antihistamine-like drugs for cancer-related pain: a narrative review. (PubMed, Support Care Cancer) - "Analysis of these studies demonstrated meaningful evidence that antihistamine and antihistamine-like drugs may offer some benefit for treating cancer-related pain."

Journal • Review • Mucositis • Oncology • Pain • Peripheral Neuropathic Pain • Stomatitis

Development of a UHPLC-MS/MS method for the quantification of DMPC and DMPG in rats and its pharmacokinetic and tissue distribution application. (PubMed, J Pharm Biomed Anal) - "DMPC, DMPG and Loratadine (internal standard, IS) were separated on an Agilent ZORBAX Extend-C18 column (2.1 mm × 50 mm, 3.5 μm particle size) by using gradient elution consisting of isopropanol-acetonitrile (90:10, v/v, 10 mM ammonium formate and 0.1 % formic acid) and water (10 mM ammonium formate and 0.1 % formic acid) at a flow rate of 0.3 mL/min in 4.0 min...However, after intravenous administration of the excipients, their half-lives were 3.5 h and 1.1-2.3 h. The observed prolongation of DMPC's half-life and concomitant shortening of DMPG's half-life are attributed to the distinct physicochemical properties of the nanoparticles."

Journal • PK/PD data • Preclinical

Modifying Mast Cell Response to Control Inflammation and Optimize Repair in Reperfused Myocardial Infarction (AHA 2025) - "In the present study we tested whether loratadine, a commonly used over-the-counter antihistamine and MC stabilizer, attenuates MVO and augments early inflammation in reperfused MIs. Twelve pigs underwent a closed-chest 90-minute ischemia-reperfusion of the left anterior descending artery and were followed through Day 5-Week 8 with LGE, cine and 18FDG-PET/MRI... Our seemingly paradoxical findings of MC stabilizer-augmented initial inflammatory response and lower subsequent ventricular volumes indicate that fine-tuning of MC degranulation post-MI could be a novel therapeutic strategy for optimized remodeling of reperfused MIs."

Cardiovascular • Inflammation • Myocardial Infarction • Reperfusion Injury

Preliminary efficacy and safety profile of dual histamine blockade on preventing filgrastim-associated bone pain in breast cancer patients: Randomized controlled trial. (PubMed, Br J Clin Pharmacol) - "The prophylactic dual histamine blockade strategy, when administered alongside filgrastim, could significantly ameliorate the incidence and severity of G-CSF-associated bone pain, and therefore improve patient's QoL. Further larger clinical studies are warranted to validate the clinical utility of this novel approach."

Journal • Breast Cancer • Musculoskeletal Pain • Oncology • Pain • Solid Tumor

Comparing Antihistamine Premedication Regimens for Preventing Rituximab-Associated Infusion Reactions in Hemato-Oncology Patients: A Retrospective Analysis (ASH 2024) - "Results : Three antihistamines were identified : diphenhydramine 50 mg, loratadine 10 mg, and cetirizine 10 mg. Using one dose of less sedating second-generation antihistamines may improve patient safety without compromising clinical efficacy. By recognizing second-generation antihistamines as a safer and equally efficacious option for rituximab premedication, standard antihistamine prescribing practices should be re-evaluated with the goal of optimizing patient safety and medication burden."

Retrospective data • Hematological Malignancies • Oncology

Comparative Analysis of Dexamethasone-Enhanced Pre-Medication in Motixafortide-Induced Hematopoietic Stem Cell Mobilization for Multiple Myeloma: A Retrospective Study (ASH 2024) - "Our first 3 patients received the recommended premedication protocol which is oral doses of diphenhydramine 25 to 50 mg, famotidine 20 mg, montelukast 10 mg, and acetaminophen 650 mg, approximately 60 minutes before injection. Patients also received loratadine 10 mg daily beginning on the day of G-CSF initiation, 3 days prior to motixafortide...Subsequently, 16 patients were started on MF-DEX, which consisted of starting famotidine 20 mg, montelukast 10 mg on the day of growth factor administration and continuing until 1 day after collection (5 days total), along with IV dexamethasone 8 mg added onto the standard premedications listed previously...Although patients who received the standard premedications had no grade 4 events and all AEs were manageable with supportive care, it was a clear burden to our patients and nursing staff. After adoption of MF-DEX our center has seen less hypersensitivity reactions and patient outcomes have improved."

Retrospective data • Dermatology • Hematological Malignancies • Immunology • Multiple Myeloma • Oncology • Pruritus • Urticaria • CD34

Use of Dupilumab in the Treatment of Bullous Pemphigoid with Type 2 Inflammatory Phenotype (ACAAI 2025) - "Initial treatment with topical corticosteroids, hydroxyzine, and loratadine was ineffective...Combination therapy with methotrexate, rituximab, and prednisone initially controlled symptoms, but flared again during tapering. The patient was subsequently initiated on dupilumab 300 mg subcutaneously every two weeks, resulting in complete clinical remission and successful steroid discontinuation. Discussion This case highlights the potential role of dupilumab as a safe and effective corticosteroid-sparing option for treatment of bullous pemphigoid in patients with a type 2 inflammatory phenotype."

Allergic Rhinitis • Atopic Dermatitis • Bullous Pemphigoid • Dermatology • Dermatopathology • Eosinophilia • Immunology • Inflammation • IL13 • IL4R

A Case of Drug-Induced Quincke's Disease (ACAAI 2025) - "He was extubated 36 hours later and discharged on prednisone, famotidine and loratadine. To date, a protocol for immediate hypersensitivity testing to nitrous oxide and MDMA is not available. This case highlights the importance of considering recreational drug exposures in patients presenting with isolated uvular angioedema and expands the limited literature on drug-induced Quincke’s disease."

Clinical • Anesthesia • Cardiovascular • Gastrointestinal Disorder • Immunology • Infectious Disease • Mood Disorders

Comparing Antihistamines for Chronic Urticaria: Systematic Review Dose Response and Network Meta-Analysis of Randomized Trials (ACAAI 2025) - "Sedation likely increases with higher doses, with first-generation agents among the most sedating; cetirizine, ketotifen, levocetirizine, and rupatadine among the intermediate sedating; and bilastine, desloratadine, fexofenadine, and loratadine among the least sedating. Cetirizine and loratadine are among the most effective for all components of urticaria activity, but cetirizine is intermediately sedating and loratadine has lower certainty on improving quality of life and sleep. Higher doses may have diminishing benefits and increased risks."

Retrospective data • Review • Anesthesia • Cardiovascular • CNS Disorders • Dermatology • Immunology • Pruritus • Sleep Disorder • Urticaria

Cold Urticaria Associated with Iron Deficiency Anemia (ACAAI 2025) - "Her symptoms temporarily resolved with antihistamines; however, they recurred and became more frequent despite taking loratadine four times a day...The exact mechanism is unknown, but literature suggests that iron depletion leads to mast cell degranulation whereas iron repletion by transferrin, lactoferrin, and lipocalins may prevent mast cell release of histamines. This case highlights the importance of evaluating those with cold urticaria for systemic causes such as iron deficiency anemia as it can offer significant benefits with low cost of testing and treatment."

Allergic Rhinitis • Anemia • Chronic Spontaneous Urticaria • Dermatology • Gynecology • Hematological Disorders • Immunology • Infectious Disease • Otorhinolaryngology • Pruritus • Respiratory Diseases • Sinusitis • Urticaria

Non-IgE Mediated Food Allergy Reaction In A Progressive Case of Pulmonary Lymphangioleiomyomatosis (ACAAI 2025) - "Loss of TSC gene function results in a clone of “LAM cells” with dysregulated mTOR (mechanistic target of rapamycin) pathway...Given her poor quality of life due to these reactions, high doses of antihistamine (loratadine with famotidine) and mast cell stabilizer (cromolyn sodium) were initiated...Discussion While LAM is primarily a cystic lung disease, there is a growing understanding that it is a multisystemic disorder with possible connections to the mast cells in the immune system. This case report of a non-IgE mediated food allergy in a progressive case of LAM may raise the flag for mast cell as an emerging target in LAM."

Clinical • Allergy • Food Hypersensitivity • Immunology • Pulmonary Disease • Solid Tumor • TSC1

Dual Biologic Therapy For Refractory Autoimmune Chronic Urticaria (ACAAI 2025) - "We present a case of autoimmune CSU refractory to guideline-recommended therapies, which ultimately required dual therapy with omalizumab and dupilumab to achieve symptom control...She did not respond to multiple first (hydroxyzine, doxepin) and second-generation antihistamines (cetirizine, loratadine, levocetirizine), as well as montelukast, and required intermittent corticosteroids during severe flares...She remains on the current regimen with tentative plans to first taper omalizumab prior to its discontinuation. Discussion This case highlights the potential for dual biologic therapy for treatment-resistant autoimmune chronic spontaneous urticaria."

Cardiovascular • Chronic Spontaneous Urticaria • Dermatology • Immunology • Urticaria

Antihistamine Treatment to Reduce Microvascular Obstruction and Hemorrhage in Reperfused Myocardial Infarction (AHA 2025) - "Loratadine treatment significantly attenuated MVO and IMH in acute MI post-reperfusion, suggesting its potential as a pharmacological intervention in acute MI. It remains to be determined whether short-term antihistamine administration translates into beneficial cardiac remodelling during the chronic phase."

Cardiovascular • Cerebral Hemorrhage • Hematological Disorders • Inflammation • Myocardial Infarction

Mast Cell Stabilization Enhances Hemorrhage Resolution and Attenuates Adverse Remodeling in Reperfused Myocardial Infarction (AHA 2025) - "Pigs with comparable MI, IMH and microvascular obstruction (MVO) sizes were randomized into untreated MI (MI, n=7) and treated (LORA, n=7) groups, with the latter given daily oral loratadine (10mg) until termination... MC stabilization accelerates hemorrhage resolution and attenuates adverse remodeling in hemorrhagic MI. However, whether overstimulated MC during myocardial ischemia/reperfusion directly exhibit reduced oxRBC scavenging potential, or it is the MC degranulation that indirectly inhibits hemorrhage resolution, remains to be determined."

Cardiovascular • Hematological Disorders • Myocardial Infarction • Myocardial Ischemia • Reperfusion Injury

Efficacy Evaluation of Omalizumab Injection in Patients with Uncontrolled Perennial Moderate-to-Severe Allergic Rhinitis: A Multicenter, Randomized, Open-Label, Investigator-Initiated Study （OPERA Study） (ChiCTR) - P4 | N=60 | Not yet recruiting | Sponsor: Yantai Yuhuangding Hospital; Yantai Yuhuangding Hospital

New P4 trial • Allergic Rhinitis • Immunology • Inflammation

An Uncommon Cause of Dysphagia: Bullous Pemphigoid with Esophageal Manifestations (ACG 2025) - "She was started on oral prednisone 40 mg daily, topical betamethasone dipropionate, and loratadine...Management typically involves systemic corticosteroids; immunosuppressants like mycophenolate or rituximab may be used for refractory cases. Adjunctive therapies include acid suppression, diet modification, and cautious endoscopic dilation if strictures develop. Early recognition is key to preventing complications, and interdisciplinary care between dermatology and gastroenterology ensures optimal outcomes.Figure: Endoscopy demonstrating concentric rings"

Bullous Pemphigoid • Dermatology • Dermatopathology • Eosinophilic Esophagitis • Gastroenterology • Gastroesophageal Reflux Disease • Gastrointestinal Disorder • Immunology

Proton Pump Panic: A Shocking Surprise by Pantoprazole (ACG 2025) - "She was subsequently admitted for the management of anaphylactic shock and received epinephrine intramuscularly along with fluid boluses with improvement in her symptoms within hours...She was initiated on systemic steroids and loratadine for supportive care. Pantoprazole was switched to famotidine 40 mg twice daily on discharge. PPIs are widely used medications for gastrointestinal disorders in the United States due to their increased potency and better tolerance than H2 receptor antagonists, easy over-the-counter availability, and affordability causing its exploitation for non-FDA approved conditions including uninvestigated dyspepsia, Barrett's esophagus, esophageal stricture, risk reduction for NSAID associated peptic ulcer...This case demands judicious medication use and efforts at even de-prescribing it when not indicated or no longer effective. It also highlights the importance of emergent recognition and management of adverse reactions like anaphylaxis by..."

Barrett Esophagus • Dyspepsia • Gastroenterology • Gastroesophageal Reflux Disease • Gastrointestinal Disorder • Hematological Disorders • Hepatology • Immunology • Inflammation • Nephrology • Osteoporosis • Peptic Ulcer • Pruritus • Rheumatology • Steven-Johnson Syndrome • Thrombocytopenia

Efficacy comparison of combined montelukast-antihistamine and montelukast monotherapy in allergic rhinitis: a meta-analysis of randomized controlled trials. (PubMed, Eur Ann Allergy Clin Immunol) - "In subgroup analysis, all combinations with loratadine, desloratadine, or levocetirizine showed greater efficacy than monotherapy in improving daytime symptoms. However, the effectiveness of each drug combination varied by symptom domain. These findings may assist clinicians in selecting appropriate combination regimens based on individual symptom patterns."

Journal • Monotherapy • Retrospective data • Review • Allergic Rhinitis • Conjunctivitis • Immunology • Inflammation • Ocular Infections • Ocular Inflammation • Ophthalmology

BEYOND THE BARK: EXPLORING THE ROLE OF BIOLOGICS IN ALLERGIC CROUP (CHEST 2025) - "Emergency department management included racemic epinephrine and intramuscular dexamethasone, with discharge after observation...Given the strong allergic component treatment with loratadine for allergic rhinitis and albuterol as needed was initiated. A steroid regimen (prednisone) was prescribed for exacerbations... This case suggests the possible link between allergic mechanisms, type 2 inflammation, and recurrent crou and targeted biologic therapies like Dupilumab may present a promising treatment for managing allergic croup unresponsive t standard therapies. Further research is needed in investigating and exploring the the role of Dupilumab and other biologic therapies in treating allergic croup."

Allergic Rhinitis • Allergy • Asthma • Atopic Dermatitis • Cough • Dermatitis • Dermatology • Eosinophilia • Eosinophilic Esophagitis • Gastrointestinal Disorder • Inflammation • Metabolic Disorders • Pediatrics • Respiratory Diseases • IL13 • IL4

Hypochlorination of Loratadine: Chemical identification and ecotoxicological effects of derivative byproducts. (PubMed, Sci Total Environ) - "Conversely, LORA induced only a 38 % effect at 2000 ng/L, indicating higher chronic toxicity of DBPs compared to the parent compound. These results underscore the environmental relevance of LORA DBPs, which may pose a higher chronic risk to aquatic organisms than the parent compound, especially under typical water treatment conditions."

Journal

From simulation to application: enhancing preclinical evaluation of dissolvable microarray patches through PBPK modelling. (PubMed, Drug Deliv Transl Res) - "In this study, an existing dermal PBPK model in MoBi® was optimised for dissolvable MAP by incorporating microneedle geometry and in vitro release profiles of MAP formulations containing the antihistamines loratadine (LOR) and chlorpheniramine maleate (CPM), as well as the antifungal drug itraconazole (ITZ). Validation was performed using in vitro permeation testing with porcine skin for CPM and LOR MAP, alongside in vivo preclinical studies in pigs for ITZ MAP. The optimised model demonstrated robust predictive performance across the diverse drug molecules and experimental conditions investigated, highlighting its value as a powerful tool to accelerate preclinical MAP development."

Journal • Preclinical

Impact of metabolic enzyme activity variability on dabrafenib disposition. (PubMed, Front Pharmacol) - "Both loratadine-mediated drug-drug interactions and CYP3A4 genetic polymorphisms critically alter the metabolism of dabrafenib. Dosage adjustments are necessary when these factors are present concurrently."

Journal • CYP3A4